Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $394.35 million. The enterprise value is $341.26 million.
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 96.65 million shares outstanding. The number of shares has increased by 83.71% in one year.
| Current Share Class | 96.65M |
| Shares Outstanding | 96.65M |
| Shares Change (YoY) | +83.71% |
| Shares Change (QoQ) | -8.57% |
| Owned by Insiders (%) | 16.61% |
| Owned by Institutions (%) | 66.67% |
| Float | 53.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 49.83 |
| Forward PS | 32.22 |
| PB Ratio | 10.17 |
| P/TBV Ratio | 10.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 43.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.65, with a Debt / Equity ratio of 0.93.
| Current Ratio | 9.65 |
| Quick Ratio | 9.39 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.30 |
Financial Efficiency
Return on equity (ROE) is -615.57% and return on invested capital (ROIC) is -94.57%.
| Return on Equity (ROE) | -615.57% |
| Return on Assets (ROA) | -58.54% |
| Return on Invested Capital (ROIC) | -94.57% |
| Return on Capital Employed (ROCE) | -72.01% |
| Weighted Average Cost of Capital (WACC) | 8.24% |
| Revenue Per Employee | $282,643 |
| Profits Per Employee | -$4.88M |
| Employee Count | 28 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +117.02% in the last 52 weeks. The beta is 0.80, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +117.02% |
| 50-Day Moving Average | 4.39 |
| 200-Day Moving Average | 4.30 |
| Relative Strength Index (RSI) | 50.23 |
| Average Volume (20 Days) | 1,037,513 |
Short Selling Information
The latest short interest is 10.86 million, so 11.24% of the outstanding shares have been sold short.
| Short Interest | 10.86M |
| Short Previous Month | 13.34M |
| Short % of Shares Out | 11.24% |
| Short % of Float | 20.39% |
| Short Ratio (days to cover) | 6.72 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $7.91 million and -$136.65 million in losses. Loss per share was -$1.50.
| Revenue | 7.91M |
| Gross Profit | -38.79M |
| Operating Income | -61.54M |
| Pretax Income | -136.65M |
| Net Income | -136.65M |
| EBITDA | -61.48M |
| EBIT | -61.54M |
| Loss Per Share | -$1.50 |
Full Income Statement Balance Sheet
The company has $88.97 million in cash and $35.88 million in debt, with a net cash position of $53.09 million or $0.55 per share.
| Cash & Cash Equivalents | 88.97M |
| Total Debt | 35.88M |
| Net Cash | 53.09M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 38.43M |
| Book Value Per Share | 0.40 |
| Working Capital | 85.02M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$48.55 million and capital expenditures -$189,000, giving a free cash flow of -$48.74 million.
| Operating Cash Flow | -48.55M |
| Capital Expenditures | -189,000 |
| Depreciation & Amortization | 62,000 |
| Net Borrowing | 35.00M |
| Free Cash Flow | -48.74M |
| FCF Per Share | -$0.50 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | -777.66% |
| Pretax Margin | -1,726.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -83.71% |
| Shareholder Yield | -83.71% |
| Earnings Yield | -36.71% |
| FCF Yield | -12.36% |
Analyst Forecast
The average price target for Opus Genetics is $13.94, which is 241.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.94 |
| Price Target Difference | 241.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 45.80% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -2.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.67 |
| Piotroski F-Score | 2 |